Wedbush Analysts Reduce Earnings Estimates for Albireo Pharma Inc (ALBO)

Share on StockTwits

Albireo Pharma Inc (NASDAQ:ALBO) – Research analysts at Wedbush reduced their Q2 2019 earnings per share (EPS) estimates for Albireo Pharma in a report issued on Monday, May 13th. Wedbush analyst L. Moussatos now anticipates that the biopharmaceutical company will post earnings per share of ($1.42) for the quarter, down from their previous estimate of ($1.37). Wedbush has a “Buy” rating and a $69.00 price objective on the stock. Wedbush also issued estimates for Albireo Pharma’s Q3 2019 earnings at ($1.36) EPS, Q4 2019 earnings at ($1.37) EPS, FY2019 earnings at ($5.54) EPS, Q1 2020 earnings at ($1.37) EPS, Q2 2020 earnings at ($1.36) EPS, Q3 2020 earnings at ($1.34) EPS, Q4 2020 earnings at ($1.34) EPS, FY2020 earnings at ($5.41) EPS, FY2021 earnings at ($8.29) EPS, FY2022 earnings at ($3.02) EPS and FY2023 earnings at $4.60 EPS.

Albireo Pharma (NASDAQ:ALBO) last announced its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.37) by ($0.02). Albireo Pharma had a negative return on equity of 47.03% and a negative net margin of 2,900.81%. The company had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $1.20 million.

A number of other equities analysts also recently commented on the company. HC Wainwright started coverage on Albireo Pharma in a research report on Thursday, February 28th. They set a “buy” rating and a $62.00 price objective on the stock. BidaskClub upgraded Albireo Pharma from a “buy” rating to a “strong-buy” rating in a research report on Friday, May 3rd. ValuEngine upgraded Albireo Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, February 28th. Zacks Investment Research downgraded Albireo Pharma from a “hold” rating to a “sell” rating in a research report on Monday, March 11th. Finally, Cowen reiterated a “buy” rating on shares of Albireo Pharma in a research report on Wednesday, April 17th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Albireo Pharma presently has a consensus rating of “Buy” and a consensus target price of $54.25.

Shares of Albireo Pharma stock opened at $35.98 on Thursday. Albireo Pharma has a one year low of $19.10 and a one year high of $38.69. The company has a market cap of $455.81 million, a P/E ratio of -9.13 and a beta of 1.72.

A number of large investors have recently bought and sold shares of ALBO. Man Group plc purchased a new stake in Albireo Pharma during the 1st quarter valued at approximately $701,000. M&T Bank Corp purchased a new stake in Albireo Pharma during the 1st quarter valued at approximately $201,000. ArrowMark Colorado Holdings LLC raised its stake in Albireo Pharma by 7.9% during the 1st quarter. ArrowMark Colorado Holdings LLC now owns 660,442 shares of the biopharmaceutical company’s stock valued at $21,273,000 after acquiring an additional 48,450 shares during the last quarter. Geode Capital Management LLC raised its stake in Albireo Pharma by 11.6% during the 1st quarter. Geode Capital Management LLC now owns 108,716 shares of the biopharmaceutical company’s stock valued at $3,501,000 after acquiring an additional 11,282 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in Albireo Pharma by 7.0% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 20,440 shares of the biopharmaceutical company’s stock valued at $659,000 after acquiring an additional 1,341 shares during the last quarter. Institutional investors own 66.85% of the company’s stock.

Albireo Pharma Company Profile

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

See Also: 52-Week High/Low

Earnings History and Estimates for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.